88 related articles for article (PubMed ID: 15328183)
1. A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer.
Martin NE; Brunner TB; Kiel KD; DeLaney TF; Regine WF; Mohiuddin M; Rosato EF; Haller DG; Stevenson JP; Smith D; Pramanik B; Tepper J; Tanaka WK; Morrison B; Deutsch P; Gupta AK; Muschel RJ; McKenna WG; Bernhard EJ; Hahn SM
Clin Cancer Res; 2004 Aug; 10(16):5447-54. PubMed ID: 15328183
[TBL] [Abstract][Full Text] [Related]
2. A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer.
Hahn SM; Bernhard EJ; Regine W; Mohiuddin M; Haller DG; Stevenson JP; Smith D; Pramanik B; Tepper J; DeLaney TF; Kiel KD; Morrison B; Deutsch P; Muschel RJ; McKenna WG
Clin Cancer Res; 2002 May; 8(5):1065-72. PubMed ID: 12006520
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors.
Ryan DP; Eder JP; Puchlaski T; Seiden MV; Lynch TJ; Fuchs CS; Amrein PC; Sonnichsen D; Supko JG; Clark JW
Clin Cancer Res; 2004 Apr; 10(7):2222-30. PubMed ID: 15073096
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors.
Papadimitrakopoulou V; Agelaki S; Tran HT; Kies M; Gagel R; Zinner R; Kim E; Ayers G; Wright J; Khuri F
Clin Cancer Res; 2005 Jun; 11(11):4151-9. PubMed ID: 15930351
[TBL] [Abstract][Full Text] [Related]
5. A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.
Britten CD; Rowinsky EK; Soignet S; Patnaik A; Yao SL; Deutsch P; Lee Y; Lobell RB; Mazina KE; McCreery H; Pezzuli S; Spriggs D
Clin Cancer Res; 2001 Dec; 7(12):3894-903. PubMed ID: 11751480
[TBL] [Abstract][Full Text] [Related]
6. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
Cohen SJ; Ho L; Ranganathan S; Abbruzzese JL; Alpaugh RK; Beard M; Lewis NL; McLaughlin S; Rogatko A; Perez-Ruixo JJ; Thistle AM; Verhaeghe T; Wang H; Weiner LM; Wright JJ; Hudes GR; Meropol NJ
J Clin Oncol; 2003 Apr; 21(7):1301-6. PubMed ID: 12663718
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.
Eder JP; Ryan DP; Appleman L; Zhu AX; Puchalski T; He X; Sonnichsen DS; Cooper M; Wright J; Clark JW; Supko JG
Cancer Chemother Pharmacol; 2006 Jul; 58(1):107-16. PubMed ID: 16362299
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of intravenous bromodeoxyuridine and radiation therapy for pancreatic cancer.
Robertson JM; Ensminger WD; Walker S; Lawrence TS
Int J Radiat Oncol Biol Phys; 1997 Jan; 37(2):331-5. PubMed ID: 9069304
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
Cohen SJ; Gallo J; Lewis NL; Alpaugh RK; Gentner L; Rogatko A; Yeslow G; Schol J; Verhaeghe T; Zannikos P; Palmer PA; Weiner LM; Meropol NJ
Cancer Chemother Pharmacol; 2004 Jun; 53(6):513-8. PubMed ID: 14760509
[TBL] [Abstract][Full Text] [Related]
11. Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer.
Shinchi H; Maemura K; Noma H; Mataki Y; Aikou T; Takao S
Br J Cancer; 2007 May; 96(9):1353-7. PubMed ID: 17437021
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction.
Safran H; Akerman P; Cioffi W; Gaissert H; Joseph P; King T; Hesketh PJ; Wanebo H
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):53-7. PubMed ID: 10210540
[TBL] [Abstract][Full Text] [Related]
13. A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
Patnaik A; Eckhardt SG; Izbicka E; Tolcher AA; Hammond LA; Takimoto CH; Schwartz G; McCreery H; Goetz A; Mori M; Terada K; Gentner L; Rybak ME; Richards H; Zhang S; Rowinsky EK
Clin Cancer Res; 2003 Oct; 9(13):4761-71. PubMed ID: 14581347
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.
Ikeda M; Okusaka T; Ito Y; Ueno H; Morizane C; Furuse J; Ishii H; Kawashima M; Kagami Y; Ikeda H
Br J Cancer; 2007 Jun; 96(11):1650-5. PubMed ID: 17533388
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
Crul M; de Klerk GJ; Swart M; van't Veer LJ; de Jong D; Boerrigter L; Palmer PA; Bol CJ; Tan H; de Gast GC; Beijnen JH; Schellens JH
J Clin Oncol; 2002 Jun; 20(11):2726-35. PubMed ID: 12039935
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
Sudo K; Yamaguchi T; Ishihara T; Nakamura K; Shirai Y; Nakagawa A; Kawakami H; Uno T; Ito H; Saisho H
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):219-24. PubMed ID: 17189072
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
Jiang Y; Mackley HB; Kimchi ET; Zhu J; Gusani N; Kaifi J; Staveley-O'Carroll KF; Belani CP
Cancer Chemother Pharmacol; 2014 Jul; 74(1):205-10. PubMed ID: 24908435
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras.
Brunner TB; Cengel KA; Hahn SM; Wu J; Fraker DL; McKenna WG; Bernhard EJ
Cancer Res; 2005 Sep; 65(18):8433-41. PubMed ID: 16166322
[TBL] [Abstract][Full Text] [Related]
19. A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors.
Moulder SL; Mahany JJ; Lush R; Rocha-Lima C; Langevin M; Ferrante KJ; Bartkowski LM; Kajiji SM; Noe DA; Paillet S; Sullivan DM
Clin Cancer Res; 2004 Nov; 10(21):7127-35. PubMed ID: 15534083
[TBL] [Abstract][Full Text] [Related]
20. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
